Retatrutide Dosage Guide: Titration Schedules, Trial Data & Regulatory Status (2026)

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Published / Reviewed July 24, 2026 · Written by Sam Brooks

Is Retatrutide FDA-Approved? The Short Answer

No. Retatrutide is not FDA-approved for any use as of July 24, 2026. It is an investigational, “triple-G” (GIP, GLP-1, and glucagon receptor) agonist being developed by Eli Lilly and studied in the Phase 3 TRIUMPH program for obesity and related metabolic conditions. Because it is unapproved, there is no FDA-cleared label, no approved dose, and no lawful commercial supply. Products sold online as “research retatrutide” are not manufactured, tested, or dosed to any approved standard, and BHRC does not endorse or supply them.

Quick Retatrutide Dosing Summary

In clinical trials, retatrutide is given as a once-weekly subcutaneous injection using a slow, stepwise dose escalation (titration) that starts at 1 mg and climbs, every four weeks, toward a maintenance dose. The two published programs used different ladders: the Phase 2 trial escalated 1 → 2 → 4 → 8 → 12 mg (no 6 mg step), while the Phase 3 TRIUMPH program uses 1 → 2 → 4 → 6 → 9 → 12 mg. The maximum dose studied is 12 mg weekly. None of this is a prescribing instruction — it is a description of trial protocols.

The Two Published Titration Schedules at a Glance

Note: exact week boundaries varied by cohort and escalation regimen within each program. The table shows the representative ladder each program used, not a personalized schedule.

Fast Facts Table

If you are exploring physician-supervised, FDA-cleared weight-management options that are available today, you can schedule a peptide therapy consultation with a BHRC clinician to discuss approved therapies.

What Is Retatrutide (LY3437943)?

Retatrutide is a single, synthetic peptide engineered to activate three different metabolic hormone receptors at once. It is the next conceptual step beyond semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist). By adding glucagon-receptor activity, retatrutide is designed not only to reduce appetite and slow gastric emptying but also to increase energy expenditure and influence hepatic fat metabolism. It remains investigational, and every statement about its effects reflects trial findings rather than an approved indication.

The “Triple-G” Triple Agonist Mechanism

The three receptor targets each contribute differently:

• GLP-1 receptor agonism — reduces appetite, slows gastric emptying, and improves glucose-dependent insulin secretion. This is the mechanism shared with semaglutide.
• GIP receptor agonism — modulates appetite and insulin sensitivity and is thought to blunt some GLP-1-related nausea. This is shared with tirzepatide.
• Glucagon receptor agonism — the distinguishing third arm. Glucagon-receptor activity can raise energy expenditure and promote lipolysis and hepatic fat oxidation. It also explains why heart rate and certain metabolic parameters need careful monitoring in trials.

A C20 fatty-diacid chain added to the molecule promotes albumin binding, which is what extends the half-life to roughly six days and allows convenient once-weekly dosing in the trials. Because albumin binding acts like a slow-release reservoir, plasma concentrations rise and fall gradually rather than spiking, which supports steady receptor engagement across the week and is part of why a single weekly injection is sufficient.

Balancing three receptors is also what makes retatrutide clinically interesting and clinically demanding. Glucagon agonism, taken alone, would tend to raise blood glucose — the opposite of what you want in metabolic disease. Retatrutide’s design pairs that glucagon activity with strong GLP-1 and GIP incretin effects, which drive glucose-dependent insulin release and appetite suppression, so that the net effect in trials has been weight loss and, in diabetes studies, improved glucose control. The molecule is essentially a carefully tuned compromise, and the intermediate titration steps exist so the body can adapt to that combined signaling gradually.

How Retatrutide Differs From Semaglutide and Tirzepatide

The practical headline is receptor count and, in early data, magnitude of effect. Semaglutide targets one receptor; tirzepatide targets two; retatrutide targets three. In separate trials (not head-to-head), retatrutide’s highest doses produced larger average weight reductions than have typically been reported for single- or dual-agonist therapies. However, semaglutide and tirzepatide are FDA-approved with large safety databases and clear labeling, while retatrutide is still investigational. More receptors is not automatically “better” for a given person — it also changes the side-effect profile, as covered below.

The glucagon arm is the crux of the difference. In semaglutide and tirzepatide, weight loss is driven almost entirely by reduced calorie intake through appetite suppression and slowed gastric emptying. Retatrutide adds a second lever: increased energy expenditure and enhanced fat mobilization from the glucagon-receptor effect. In theory, that means the body burns modestly more energy in addition to eating less. This dual mechanism is the leading hypothesis for why retatrutide’s weight-loss numbers ran higher in trials, and it is also why the drug produced effects — such as a larger heart-rate rise — that the single- and dual-agonist drugs show to a lesser degree. It is a genuinely different pharmacologic profile, not simply a stronger version of the same drug.

Development Status and the TRIUMPH Program

Retatrutide’s obesity development is anchored by the Phase 3 TRIUMPH program (a series of trials including obesity, obesity with type 2 diabetes, and knee osteoarthritis in obesity). Phase 2 results in obesity were published in the New England Journal of Medicine in 2023 (Jastreboff et al.), and additional Phase 2 work has examined type 2 diabetes and metabolic-dysfunction-associated steatotic liver disease (MASLD). Phase 3 readouts have begun reporting, but the drug has not completed regulatory review. Until it does, dosing “schedules” you see online are trial-derived, not an approved regimen.

Beyond obesity, the Phase 2 program has generated notable secondary signals. A Phase 2 trial in adults with type 2 diabetes reported meaningful reductions in HbA1c along with weight loss, and a Phase 2a trial in people with MASLD reported substantial reductions in liver fat content, with a large share of participants reaching normal or near-normal liver-fat levels at higher doses. These findings are why retatrutide is often described as a potential “metabolic” drug rather than only a weight-loss drug. They remain investigational results, and none of them establishes an approved use. The breadth of the TRIUMPH program — spanning weight, glucose, liver, and joint outcomes — reflects Eli Lilly’s strategy of testing the triple-agonist concept across several obesity-linked conditions simultaneously, but regulatory approval, if it comes, will be granted one indication at a time based on completed Phase 3 evidence.

Retatrutide Dosing Protocols Based on Clinical Research

This section summarizes how retatrutide was studied. It is not a protocol to follow at home. All figures are for context and must be interpreted by a qualified physician within an appropriate clinical setting.

Standard Dose Ranges Studied (1–12 mg)

Across the obesity trials, weekly doses ranged from a 1 mg tolerance-building starting dose up to a 12 mg maximum maintenance dose. The intermediate steps (2, 4, 6, 8, and 9 mg) exist primarily to let the body adapt to the strong appetite and gastrointestinal effects before reaching a therapeutic maintenance dose. The 1 mg starting dose is explicitly a tolerability step and is not expected to drive meaningful weight change on its own.

An important nuance is that not every participant needs to reach 12 mg to benefit. In the trials, meaningful weight loss was seen at intermediate maintenance doses such as 4 mg and 8 mg, and in real clinical practice with approved drugs of this class, many people do best at a mid-range dose they tolerate well rather than the ceiling dose. “Highest dose” and “right dose” are not synonyms. The maximum studied dose defines the top of the investigated range; it does not imply that everyone should aim for it. This is a core reason dosing decisions belong with a clinician who can weigh response, side effects, and goals together, rather than with a chart alone.

Phase 2 (NEJM) vs Phase 3 (TRIUMPH) Titration — Side by Side

The single most useful thing this guide can clarify is that there is no one “retatrutide titration schedule.” There are two published ladders, and they differ:

• Phase 2 (Jastreboff et al., NEJM 2023): escalated 1 → 2 → 4 → 8 → 12 mg. The jump from 4 mg straight to 8 mg is large, and the trial actually tested two different escalation speeds to study tolerability.
• Phase 3 (TRIUMPH): uses 1 → 2 → 4 → 6 → 9 → 12 mg. Two additional rungs — 6 mg and 9 mg — smooth out the climb.

See the side-by-side titration table in the Quick Summary above for the week-by-week comparison.

Why the Schedules Differ: The 6 mg Step

The Phase 3 program’s added 6 mg (and 9 mg) steps reflect a lesson learned in Phase 2: the biggest driver of nausea, vomiting, and dropout with these agents is how fast you escalate, not just the final dose. By inserting gentler increments, the TRIUMPH design aims to reach the same 12 mg maximum with fewer gastrointestinal adverse events. This is why searching “retatrutide 6 mg” returns conflicting answers — 6 mg is a real step in Phase 3 but does not exist in the Phase 2 ladder.

Clinical Trial Dosing Data

In the Phase 2 obesity trial, 338 adults with obesity (or overweight with a weight-related condition) were randomized to placebo or retatrutide at maintenance targets of 1, 4, 8, or 12 mg once weekly for 48 weeks. Escalation occurred over roughly the first 12–20 weeks depending on the target dose, followed by maintenance. Mean weight reduction was dose-dependent, reaching about 24.2% at 48 weeks in the 12 mg arm, with roughly 17.5% by 24 weeks at the highest dose — and, notably, the weight-loss curve had not clearly plateaued by week 48.

The absence of a clear plateau is one of the most-cited features of the Phase 2 data. With many weight-loss interventions, the curve flattens well before the end of the study as the body reaches a new equilibrium. In the retatrutide 12 mg arm, participants were still losing weight when the 48-week trial ended, which raised the question of how much more loss longer exposure might produce. The Phase 3 TRIUMPH trials, running far longer than 48 weeks, were designed in part to answer that question — and the higher totals reported in Phase 3 (up to roughly 30%) are consistent with the idea that longer treatment yields greater cumulative loss, at least to a point. It is important to read these numbers as trial averages under close supervision, with substantial person-to-person variation around the mean; some participants lost far more, and others far less.

The Phase 2 trial also deliberately studied two escalation regimens at the 8 mg and 12 mg targets — one faster and one slower — specifically to understand how titration speed affects tolerability. That embedded comparison is the source of the widely quoted nausea contrast discussed below, and it is a big reason the Phase 3 program adopted a more gradual ladder.

Maintenance Dose Arms

Values are rounded approximations drawn from published summaries and press releases. Longer Phase 3 trials generally show larger totals partly because of their longer duration. These are population averages in supervised trials, not guarantees of individual results.

Why Titration Matters: The Nausea Data

Most competing pages list a dose ladder and stop there. The more important clinical point is that titration speed materially changes tolerability. This is one of the best-documented differentiators in the retatrutide data set.

60% vs 17% — What Skipping the 2 mg Step Does

The takeaway is dramatic: escalating too quickly can more than triple nausea rates without improving long-term weight loss. This is precisely why “just start at a higher dose to lose weight faster” is both unsupported and, in an unsupervised setting, dangerous. In the approved-drug world, this same principle is why physicians never rush GLP-based titration.

The mechanism behind this is straightforward. The gastrointestinal side effects of incretin-based drugs are largely driven by the rate of receptor activation, not just the absolute dose. When the dose climbs slowly, the gut’s motility and signaling systems adapt at each step, and nausea tends to be transient. When the dose jumps too fast, that adaptation cannot keep pace, and nausea, vomiting, and dehydration become far more likely — which in turn drives people to abandon treatment. Because the long-term weight-loss endpoint is set by the maintenance dose that a person can actually stay on, rushing the climb is self-defeating: it does not speed results and it increases the odds of dropping out entirely. Slower is not just more comfortable; in this drug class it is frequently more effective over the full course.

Slow Titration Principles

Trial experience with retatrutide reinforces several principles common to this drug class:

• Hold each step for about four weeks before advancing.
• Do not advance while significant nausea, vomiting, or dehydration is present.
• Consider staying longer at a tolerated dose rather than pushing to the next rung on schedule.
• The goal is the lowest effective dose that a person tolerates — not the maximum dose.

These principles are provider-directed. They are shared here to explain the science, not to enable self-escalation.

How Retatrutide Is Reconstituted (Educational Only)

Why This Section Is Educational, Not Instructional

Step-by-Step Reconstitution Concept

In principle, lyophilized (freeze-dried) peptides are reconstituted by adding bacteriostatic water to the vial. Conceptually the process a clinician would follow is:

1. Allow refrigerated components to reach room temperature and disinfect all vial stoppers.
2. Draw a measured volume of bacteriostatic water into a sterile syringe.
3. Add the water slowly down the inside wall of the peptide vial rather than directly onto the powder.
4. Swirl gently — never shake — until fully dissolved and clear.
5. Store per manufacturer guidance and discard if cloudy or particulate.

Because retatrutide is not sold as an approved, standardized vial, there is no legitimate label to define its concentration — another reason this section is conceptual only.

Dosing Calculation Examples (Syringe-Unit Math)

To show how concentration math works in general (using an illustrative peptide, not real retatrutide product):

• Insulin syringes are marked in “units,” where 100 units = 1 mL.
• If a vial contained 10 mg of peptide reconstituted with 2 mL of water, the concentration would be 5 mg/mL, i.e., 0.05 mg per unit.
• A hypothetical 4 mg dose would then be 80 units (4 ÷ 0.05).
• A hypothetical 6 mg dose would be 120 units, which exceeds a standard 100-unit syringe and would require a different fill volume or split — the kind of nuance a clinician handles.

The point of showing the math is to illustrate how easily a self-mixer can misdose by an order of magnitude — a real and serious risk with an unstandardized product.

Concentration Reference Table

These rows demonstrate arithmetic only. They do not correspond to any real retatrutide product, dose, or recommendation.

Retatrutide Administration in Clinical Trials

In trials, retatrutide is given subcutaneously by trained participants under investigator oversight, mirroring the technique used for approved once-weekly injectables.

Injection Site Selection

Standard subcutaneous sites for weekly agents include the abdomen (avoiding the area right around the navel), the front of the thighs, and the back of the upper arms. Trials emphasize consistent, clean technique rather than any single “best” site. Absorption from subcutaneous tissue is relatively consistent across these sites for long-acting, albumin-bound peptides, which is part of why once-weekly agents in this class do not require the same rigid site discipline that rapid-acting insulin does. Even so, avoiding scarred, bruised, or irritated skin improves comfort and predictability.

Subcutaneous Injection Technique

General subcutaneous technique used across this drug class involves cleaning the site, pinching the tissue if appropriate, injecting at the recommended angle, and disposing of sharps safely. Because retatrutide has no approved delivery device, there is no validated real-world administration format for personal use. The approved drugs in this class ship in pre-filled, single-use pen devices precisely so that dose accuracy, sterility, and needle safety are handled by design rather than left to the user. That engineering — a fixed, verified dose in a sealed device — is one of the quiet but important safety features that grey-market vials lack entirely. A person drawing an unknown-concentration liquid from a multi-use vial with a manual syringe is exposed to dosing error, contamination on repeated entry, and needle-stick risk, none of which exist with an approved pen.

Rotation and Handling

Rotating injection sites week to week reduces local irritation and lipohypertrophy. Cold-chain handling and expiration discipline matter for any biologic — and cannot be verified for grey-market material, which is one more reason unapproved supply is unsafe.

Optimal Timing for Retatrutide Administration

Same Day Each Week

Because of the ~6-day half-life, retatrutide is dosed once weekly, ideally on the same day each week, with or without food. Consistent timing keeps plasma levels steady and simplifies adherence.

Managing a Missed Dose (Trial Protocols)

In studies of weekly agents, a missed dose is generally taken as soon as reasonably possible if several days remain before the next scheduled dose; if the next dose is near, the missed one is skipped rather than doubled. Investigators, not patients, make these calls in a trial. Never “double up” to catch up.

Retatrutide Cycle Length and Protocol Duration

Escalation Phase

The escalation phase spans roughly the first 16–24 weeks depending on the target dose and program, moving up one step approximately every four weeks. This is the highest-risk window for gastrointestinal side effects.

Maintenance Phase

After reaching a tolerated maintenance dose, trials continue for many months — Phase 3 arms run well beyond a year (e.g., ~68–80 weeks) — because obesity is treated as a chronic condition, not a short course. This is unlike short “cycles” some people associate with other peptides.

Discontinuation and Weight Regain

As with approved GLP-based drugs, stopping treatment typically leads to partial weight regain over time, because the underlying appetite and metabolic setpoints reassert themselves. Any long-term strategy — for approved agents — should be planned with a physician, not started and stopped impulsively. This point is frequently misunderstood: these medications do not “cure” obesity, they treat it while present, much as a blood-pressure medication controls hypertension only while it is being taken. The clinical implication is that durable results depend on a durable plan, whether that means continued therapy at a maintenance dose, a carefully supervised taper, or a robust lifestyle framework built during treatment. For an unapproved drug with no supply chain, none of this can be responsibly managed, which is one more reason retatrutide is not a do-it-yourself proposition.

Retatrutide Safety Profile and Potential Side Effects

Retatrutide’s safety database is still maturing. The most consistent findings across trials are gastrointestinal effects during escalation, plus a few signals worth highlighting.

Common Adverse Events

Dysesthesia and Heart-Rate Signals

Two effects distinguish retatrutide from single/dual agonists and deserve emphasis. First, dysesthesia — abnormal skin sensations such as tingling or prickling — appeared in about one in five participants at the 12 mg dose in Phase 3, far above placebo. Second, retatrutide raised resting heart rate by roughly 5–7 bpm on average, peaking around week 24 before easing. The glucagon-receptor arm likely contributes to the heart-rate signal, which is one reason cardiovascular monitoring is built into the trials.

Dysesthesia is worth understanding because it is unusual for this drug class and appears to be more prominent with retatrutide than with GLP-1 or GLP-1/GIP agents. In the trials it was generally described as mild-to-moderate tingling, prickling, or altered sensation, most often at the highest dose, and it was more common during the higher-dose phase. Its exact mechanism is not fully established, and long-term follow-up is part of what the Phase 3 program is designed to characterize. A resting heart-rate increase of several beats per minute may sound minor, but in a population that may already carry cardiovascular risk it is clinically relevant, which is precisely why heart rate and blood pressure are monitored throughout the trials and why anyone with significant cardiac disease would be evaluated carefully. Neither of these signals is something a person could safely self-monitor while using an unregulated product, and both underscore why retatrutide belongs in a supervised setting.

Contraindications

Because retatrutide is investigational, formal contraindications are defined by trial exclusion criteria rather than an FDA label. Based on the drug class, populations generally excluded or treated with heightened caution include people with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, severe gastrointestinal disease such as gastroparesis, pregnancy or breastfeeding, and certain uncontrolled cardiovascular conditions. Only an investigator can determine eligibility.

Drug Interactions

Like other GLP-based agents, retatrutide slows gastric emptying, which can alter the absorption of oral medications and may enhance the glucose-lowering effect of insulin or sulfonylureas, raising hypoglycemia risk. Interactions in an investigational agent are managed by the study team. Delayed gastric emptying is particularly relevant for medications where timing and consistent absorption matter — for example, certain oral contraceptives, thyroid hormone, and drugs with a narrow therapeutic window. There has also been broader attention across this drug class to retained gastric contents during procedures requiring sedation or general anesthesia, which is why anesthesia and surgical teams increasingly ask about GLP-based medication use beforehand. All of these considerations are handled by clinicians within a trial, and all of them are further reasons the drug is inappropriate to use without supervision.

Retatrutide vs Tirzepatide vs Semaglutide: Comparison

The most common comparison query is retatrutide vs tirzepatide. Here is a side-by-side matrix. Remember that only tirzepatide and semaglutide are FDA-approved and available; retatrutide is not.

Mechanism and Efficacy Matrix

When Each Is Studied For

If you are weighing options that are actually available today, semaglutide and tirzepatide are the physician-prescribed, FDA-approved choices — and BHRC clinicians can discuss whether either is appropriate. Retatrutide’s larger trial numbers are promising but come with a still-maturing safety database, no approval, and no lawful supply. For most people asking “should I use retatrutide,” the accurate answer in 2026 is: it is not available outside a trial, and an approved agent is the appropriate path to discuss with a clinician.

It is also worth resisting the temptation to read cross-trial numbers as a definitive ranking. The percentages for semaglutide, tirzepatide, and retatrutide come from different studies, with different populations, durations, endpoints, and eras of care. A ~24% figure at 48 weeks for retatrutide and a ~15% figure at 68 weeks for semaglutide are not a like-for-like contest — they are separate experiments that happen to be quoted side by side. Only a properly designed head-to-head trial can establish true comparative efficacy, and for retatrutide versus the approved agents, that definitive comparison in the obesity setting is still limited. The honest summary is that retatrutide looks highly promising and mechanistically distinct, but “most powerful” remains a hypothesis being tested rather than a settled, approved fact. What matters for an individual is not the headline percentage but which available, appropriate therapy fits their health profile and goals — a determination that belongs with a clinician who can order labs, review history, and monitor response.

Who Would Be a Candidate in Trials?

Trial Inclusion Criteria

Retatrutide obesity trials generally enroll adults with obesity (commonly BMI ≥30) or overweight (BMI ≥27) plus a weight-related condition, without disqualifying medical histories. Some trials specifically enroll people with type 2 diabetes, MASLD, or obesity-related osteoarthritis. Enrollment is through registered studies, not clinics that sell the drug. Interested individuals can search ClinicalTrials.gov for active retatrutide or TRIUMPH studies, review the inclusion and exclusion criteria for each, and contact the listed study sites directly. Participation is free of charge for the study drug and study-related care, and it comes with the protections of informed consent, an ethics-board-reviewed protocol, and ongoing medical monitoring — protections that are entirely absent when someone buys an unapproved peptide online.

Who Should Not Use It

Beyond formal exclusions, retatrutide is inappropriate for anyone outside a supervised trial simply because there is no approved, quality-assured product. People who are pregnant or breastfeeding, who have relevant thyroid cancer history, pancreatitis history, or significant GI or cardiovascular disease would be excluded or need special caution even within trials. It is also not an appropriate tool for people seeking modest cosmetic weight loss without a genuine medical indication, for anyone unwilling or unable to commit to the monitoring these agents require, or for those looking for a short-term “cycle.” The mismatch between how these drugs are studied — as long-term, closely monitored treatment for a chronic disease — and how they are often marketed online — as a quick fix — is exactly where people get hurt. When approved GLP-based options are appropriate, a physician can help match the therapy to the person; when they are not, that same conversation can redirect toward safer strategies.

Monitoring Progress and Adjusting Protocols

What Trials Monitor

Investigators track weight and waist circumference, heart rate and blood pressure, glucose and HbA1c, liver and kidney markers, lipids, and adverse-event reporting — including the dysesthesia and heart-rate signals noted above. Dose advancement is contingent on tolerability, not the calendar alone. Because the glucagon-receptor arm can influence glucose and hepatic parameters, retatrutide trials pay particular attention to metabolic labs; and because of the heart-rate signal, cardiovascular vitals are followed closely at every visit. In diabetes cohorts, glucose-lowering co-medications may need adjustment to avoid hypoglycemia as weight and insulin sensitivity improve. This layered monitoring is the standard of care in a trial and simply cannot be reproduced by someone self-administering an unregulated product at home — which is the practical difference between “supervised research” and “guessing.”

Response Expectations by Timepoint

Averages from supervised trials; not predictive of any individual’s outcome and not achievable safely without medical oversight.

Is Retatrutide FDA-Approved? Legal & Regulatory Status (2026)

Because “is retatrutide legal” and “is retatrutide FDA approved” are among the highest-intent searches, this section states the position plainly and with a date.

Current Status

As of July 24, 2026, retatrutide is investigational and not approved by the FDA — or, to the best of our knowledge, by any comparable major regulator — for obesity, diabetes, liver disease, or any other indication. It is being studied in the Phase 3 TRIUMPH program, and Eli Lilly holds the development rights. Investigational drugs may lawfully be administered to human beings only within an authorized clinical trial, under an Investigational New Drug framework, with investigator oversight and informed consent. There is no approved label, no approved dose, and no legal pathway for a clinic, pharmacy, or individual to dispense retatrutide for general use. Any timelines you see for potential approval are projections, not facts, and this page will be updated if the regulatory status changes.

Compounding, “Research Peptide” Sellers, and Safety Risks

A large grey market advertises “retatrutide for research” in vials, often with disclaimers that it is “not for human consumption.” This framing does not make the product safe or legal to use. Because retatrutide is unapproved, it cannot be legitimately compounded for patient use the way some drugs can, and unapproved bulk peptide is outside the FDA-regulated supply chain entirely. Products sold this way carry real, documented risks: unknown purity, incorrect or misstated content, bacterial contamination, endotoxins, degraded peptide, and inaccurate dosing that can be off by large multiples. There is no manufacturer accountability, no lot testing you can trust, and no recourse if something goes wrong. BHRC does not sell, source, recommend, or facilitate access to any such product, and we strongly caution against self-administering research chemicals. The dosing figures in this guide describe supervised trials precisely so readers understand how far removed a grey-market vial is from that controlled context.

WADA / Anti-Doping Status

Athletes subject to anti-doping rules should be aware that peptide hormones and metabolic modulators are heavily scrutinized. As an investigational, non-approved substance with metabolic and performance-relevant effects, retatrutide would fall under the World Anti-Doping Agency (WADA) and USADA framework that prohibits substances “not approved by any governmental regulatory health authority for human therapeutic use” — a category explicitly banned at all times. Any athlete considering any peptide should confirm current status directly with their governing body, because using a non-approved investigational drug can result in a doping violation.

How BHRC Approaches GLP-Based Weight Management

Beverly Hills Rejuvenation Center follows the evidence and the law: we focus on FDA-approved, physician-supervised therapies with established safety records, delivered with lab work, monitoring, and lifestyle support. We do not offer, source, or endorse investigational or grey-market compounds like retatrutide. If retatrutide is eventually approved, our clinical team will evaluate it against the standard of care at that time. Until then, if you want to explore medically supervised weight-management options that are available now, our clinicians are here to help you understand what is appropriate for you. Schedule a peptide therapy consultation to start that conversation.

Conclusion

Retatrutide is one of the most closely watched investigational metabolic drugs of the decade — a triple GIP/GLP-1/glucagon agonist with trial weight-loss figures reaching the mid-20s in Phase 2 and, in early Phase 3 reporting, up to roughly 30%. The key dosing insight is that there is no single canonical schedule: the Phase 2 ladder (1 → 2 → 4 → 8 → 12 mg) and the Phase 3 TRIUMPH ladder (1 → 2 → 4 → 6 → 9 → 12 mg) differ, and the gentler Phase 3 climb reflects hard-won tolerability lessons — most vividly the finding that skipping the low 2 mg step can push nausea from roughly 17% to about 60%. But the single most important fact remains the simplest: as of July 24, 2026, retatrutide is not FDA-approved, is available only through clinical trials, and is not something BHRC prescribes, sells, or can obtain. Use this page to understand the science — and talk to a physician about approved options.

Frequently Asked Questions About Retatrutide Dosing

Is retatrutide FDA-approved?

No. As of July 24, 2026, retatrutide is investigational and not approved by the FDA for any use. It is in Phase 3 development (the TRIUMPH program) and is available only through authorized clinical trials.

What is the retatrutide titration schedule?

There are two published schedules. The Phase 2 NEJM trial escalated 1 → 2 → 4 → 8 → 12 mg weekly, while the Phase 3 TRIUMPH program uses 1 → 2 → 4 → 6 → 9 → 12 mg, advancing about every four weeks. The Phase 3 ladder adds 6 mg and 9 mg steps for a gentler climb.

What is the maximum retatrutide dose?

The highest dose studied is 12 mg once weekly. Higher doses have not been established, and 12 mg is a research maximum, not an approved dose.

Why does the Phase 3 schedule include a 6 mg step but Phase 2 does not?

The Phase 3 TRIUMPH design added 6 mg and 9 mg increments to smooth the escalation and reduce gastrointestinal side effects. Phase 2 used larger jumps (4 mg to 8 mg), which is why “retatrutide 6 mg” only appears in the Phase 3 ladder.

How much weight did people lose on retatrutide in trials?

In the Phase 2 obesity trial, the 12 mg arm averaged about 24.2% weight loss at 48 weeks. Early Phase 3 TRIUMPH reporting has described averages up to roughly 30% at the highest dose over longer durations. These are supervised-trial averages, not individual guarantees.

What is retatrutide’s half-life?

Approximately six days (about 144–165 hours), which is what allows once-weekly subcutaneous dosing. Steady state is reached after roughly four to five weekly doses.

How does retatrutide compare to tirzepatide?

Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist; retatrutide is an investigational triple agonist that adds glucagon-receptor activity. In separate (not head-to-head) trials, retatrutide’s highest doses produced larger average weight loss, but it also carries distinct effects such as dysesthesia and a larger heart-rate increase, and it is not approved or available. See our tirzepatide page for an available option.

What are the most common retatrutide side effects?

Gastrointestinal effects dominate — nausea, diarrhea, vomiting, and constipation — mostly during dose escalation. Retatrutide also showed dysesthesia (altered skin sensation) in about one in five people at 12 mg and a resting heart-rate increase of roughly 5–7 bpm that peaked around week 24.

Does titration speed really matter?

Yes, substantially. Trial data indicate that escalating too fast — effectively skipping the low 2 mg adaptation step — can raise nausea from around 17% to about 60% without improving long-term weight loss. Slow, provider-directed titration is central to tolerability.

Can I buy retatrutide or get it from BHRC?

No. BHRC does not prescribe, compound, sell, or source retatrutide, and there is no lawful commercial supply because the drug is unapproved. Products marketed online as “research retatrutide” are unregulated and not quality-assured. For FDA-approved, physician-supervised weight-management options, schedule a consultation.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. PMID: 37366315. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
2. Eli Lilly and Company. Phase 2 retatrutide results published in NEJM (up to 17.5% mean weight reduction at 24 weeks). Investor news release, 2023. https://investor.lilly.com/news-releases
3. Retatrutide for metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized Phase 2a trial. Nat Med. 2024. doi:10.1038/s41591-024-03018-2. https://www.nature.com/articles/s41591-024-03018-2
4. Rosenstock J, et al. Retatrutide in adults with type 2 diabetes: a Phase 2 randomized trial. The Lancet, 2023. (Identifier pending verification — see internal TODO.)
5. American Journal of Managed Care (AJMC). Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial. 2026. https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
6. ClinicalTrials.gov. TRIUMPH Phase 3 program for retatrutide (obesity and related conditions). U.S. National Library of Medicine. https://clinicaltrials.gov/ (search “retatrutide TRIUMPH”; specific NCT numbers to be confirmed before publish).
7. U.S. Food and Drug Administration. Drug approval status and investigational new drug information. https://www.fda.gov/ (retatrutide not listed among approved products as of 2026-07-24).

Related Resources / Related Blogs from BHRC

• Tirzepatide Therapy — the FDA-approved dual GIP/GLP-1 agonist (and our sibling tirzepatide dosing guide).
• Semaglutide Therapy — the FDA-approved GLP-1 agonist for weight management.
• CJC-1295 / Ipamorelin — growth-hormone secretagogue peptide therapy.
• AOD-9604 — a fat-metabolism peptide fragment.
• Schedule a Peptide Therapy Consultation — discuss physician-supervised, FDA-approved weight-management options with a BHRC clinician.